Last reviewed · How we verify
Myocardial Reinfarction Prevention
Approved treatments
- Inosital
Inosital works by influencing the metabolism of lipids in the body. - Lopressor · Generic (originally Ciba-Geigy/Novartis)
Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand. - Brilinta · AstraZeneca
- Brilinta · AstraZeneca
- Myoinositol · University of Colorado, Denver
- Coumadin · Generic (originally Wisconsin Alumni Research Foundation)
Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis. - Inderal · Generic (originally ICI/AstraZeneca)
- Effient · Cosette
Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots. - Eliquis · Bristol-Myers Squibb
Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development. - Plavix · Generic (originally Sanofi/BMS)
Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis. - Mevacor · Merck & Co.
Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Myocardial Reinfarction Prevention patent landscape — cliff calendar, originator estates, attackable patents
- Myocardial Reinfarction Prevention treatment landscape brief
- Myocardial Reinfarction Prevention treatment updates RSS
Frequently asked questions about Myocardial Reinfarction Prevention
What drugs treat Myocardial Reinfarction Prevention?
Tracked treatments include Inosital, Lopressor, Brilinta, Myoinositol, Coumadin, Inderal, Effient, Eliquis.
What is the treatment for Myocardial Reinfarction Prevention?
Standard treatment for Myocardial Reinfarction Prevention includes Inosital, Lopressor, Brilinta, Myoinositol, Coumadin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Myocardial Reinfarction Prevention patent cliff · Myocardial Reinfarction Prevention CI report
- Treatment: Inosital
- Treatment: Lopressor · Generic (originally Ciba-Geigy/Novartis)
- Treatment: Brilinta · AstraZeneca
- Treatment: Brilinta · AstraZeneca
- Treatment: Myoinositol · University of Colorado, Denver
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing